Small molecule · Inhibitor of Interleukin-2 inducible T-cell kinase (ITK) · developed by Corvus Pharmaceuticals
Soquelitinib is an orally available, small-molecule, irreversible inhibitor of interleukin-2 inducible T-cell kinase (ITK). It covalently binds cysteine 442 of ITK, disrupting T-cell receptor signaling, and is being studied in T-cell lymphomas.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06561048 | Phase 3 | Peripheral T-Cell Lymphoma, Not Otherwise Specified | Recruiting | CRVS |
| NCT03952078 | Phase 1 | T-cell Lymphoma | Active not recruiting | CRVS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Angioimmunoblastic T-cell LymphomaFollicular T-Cell LymphomaLymphoma, T-CellLymphoma, T-Cell, PeripheralNodal Peripheral T-Cell Lymphoma With TFH PhenotypePeripheral T-Cell Lymphoma, Not Otherwise SpecifiedSystemic Anaplastic Large Cell LymphomaT-cell Lymphoma
Updated Nov 8, 2026. Something wrong or missing? Report it on the CRVS page.
See CRVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CRVS catalysts and pipeline →